pulmonary fibrosis

February 6, 2023

Gut microbiota and lung fibrosis

Microorganisms residing in the gut influence the severity of lung fibrosis in mouse models, suggesting that modifying the gut microbiota may offer therapeutic benefit for patients.

By Leigh MacMillan
October 20, 2022

New target for lung fibrosis

Blocking thromboxane-prostanoid receptor signaling protected animals from lung fibrosis in preclinical models, suggesting a new treatment for IPF — a chronic, progressive lung disorder that often kills within 3-5 years of diagnosis.

By Leigh MacMillan
May 20, 2021

New clue to lung scarring

Vanderbilt neonatology team pinpoints signaling pathways involved in the progressive lung fibrosis that occurs in rare genetic diseases.

By Bill Snyder
lungs
July 8, 2020

New clues to lung-scarring disease may aid treatment

Scientists at Vanderbilt University Medical Center and the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, have discovered previously unreported genetic and cellular changes that occur in the lungs of people with pulmonary fibrosis (PF).

By Bill Snyder
April 2, 2020

Progression of inflammatory lung disease analyzed

A Vanderbilt University Medical Center interim analysis shows that there appears to be a considerable length of time before a subset of people develop inflammatory, scarring lung diseases where there is radiologically detectable evidence they will develop lung disease.

By Nancy Humphrey
October 4, 2018

Study reveals new targets to inhibit pulmonary fibrosis

In a study out this week in Science Translational Medicine, an international team led by researchers at Vanderbilt University Medical Center sheds new light on the cause of pulmonary fibrosis and demonstrates a way to impede the disease in mice.

By Paul Govern
April 5, 2018

Lung diseases share molecular signature

Lung diseases of infancy and aging share a molecular signature, pointing to a potential target for treatment and prevention.
By Leigh MacMillan
November 15, 2017

Radiation and pulmonary fibrosis

To develop strategies for preventing radiation-induced lung fibrosis (scarring), Vanderbilt investigators are exploring the cell types and factors that contribute to the fibrotic response.
By Leigh MacMillan
June 6, 2016

Pulmonary fibrosis culprits

New findings identify isoketal-modified proteins as a previously unrecognized feature of pulmonary fibrosis and as a potential therapeutic target for this disease.
By Leigh MacMillan
August 13, 2015

VUMC pulmonary team launches study of rare lung disease

Vanderbilt University Medical Center is launching a research study for a rare disease called Hermansky-Pudlak Syndrome (HPS), an inherited disorder that causes albinism, decreased visual acuity and susceptibility to bleeding due to platelet dysfunction.
By Craig Boerner
September 12, 2013

Federal grant bolsters pulmonary fibrosis research

Lisa Young, M.D., associate professor of Pediatrics and Medicine and Cell Biology, has been awarded a five-year, $1.9 million National Institutes of Health grant to study what causes cellular dysfunction and pulmonary fibrosis in patients with Hermansky-Pudlak syndrome (HPS).
By Christina Echegaray
April 12, 2013

Lung damage protector

Targeting repair pathways in the lung’s air sacs may be a valuable therapeutic direction for pulmonary fibrosis – the scarring of lung tissue.
By Leigh MacMillan
December 10, 2012

Genetic clues to lung scarring

A rare genetic syndrome provides new clues to lung scarring (pulmonary fibrosis), a potentially deadly consequence of many lung diseases.
By VUMC News and Communications
1 2